Rentosertib study finds lower aging-clock estimates in lung-disease patients

A study published September 7 in Nature Biotechnology reports lower protein-based estimates of biological age among lung-disease patients receiving experimental rentosertib. The findings bring aging measurements into drug development, while leaving unresolved whether the changes reflect broader aging biology or improvement in the disease being treated.

Insilico Medicine announced the analysis the same day, emphasizing agreement across six aging clocks. These computational models use blood-protein measurements to estimate age or mortality-related patterns. Agreement offers a reason to investigate further, but six models applied to the same patients do not constitute six independent clinical trials.

New analysis, earlier trial

The underlying randomized, double-blind, placebo-controlled phase 2a trial enrolled 71 patients with idiopathic pulmonary fibrosis in China. It ran in 2023–2024, and its main results were published in Nature Medicine on June 3, 2025. Rentosertib is a small-molecule inhibitor of TNIK, a protein kinase investigated as a target in fibrosis.

Participants received one of three active regimens or placebo for 12 weeks. The primary endpoint concerned treatment-emergent adverse events; lung-function measurements were secondary endpoints. Liver toxicity and diarrhea were among the most common reasons for treatment-related discontinuation. Sixteen participants discontinued treatment overall.

Those details matter when interpreting the latest report. This was a short disease-treatment trial with safety as its central objective. Its design cannot establish long-term safety for preventive use in otherwise healthy adults, and the original investigators called for larger, longer studies.

What the clocks detected

The new analysis included 42 participants, with a mean age of 67.1 years. All six clocks showed reductions in predicted biological age in treated groups. Across 54 treatment-versus-placebo comparisons spanning clocks, regimens and timepoints, 21 met the researchers’ false-discovery threshold of Q below 0.10. Signals were concentrated at week four.

The substudy used consenting trial completers with available measurements, limiting generalizability. Its authors also acknowledge that the clocks cannot separate disease-specific effects from aging effects. Several authors work for Insilico, including its chief executive.

A central interpretive question therefore remains: did treatment change a general process of aging, or did altered disease activity change proteins that the clocks also use? Either could produce scientifically useful information, but they support different clinical claims.

A biomarker needs a bridge to patient benefit

FDA guidance distinguishes a measurable biological response from an endpoint that reliably predicts clinical benefit. A biomarker can show that something changed after treatment without demonstrating that patients feel better, function better or survive longer.

For a biomarker to serve as a validated surrogate endpoint, clinical evidence must establish that treatment-induced changes predict a specific benefit in the relevant setting. Even a surrogate validated for one use can mislead in another, because it may miss harmful effects elsewhere.

Applied here, that framework argues against translating a clock change into years of life gained. The practical next question is whether similar changes consistently accompany durable improvements in outcomes patients experience, with an acceptable safety profile.

For healthspan research, embedding biological measurements in disease trials may help generate testable hypotheses and identify promising mechanisms. The current result supports that research direction. Establishing a preventive benefit would require additional evidence connecting the measurements to sustained health, beyond the short-term response of patients already living with pulmonary fibrosis.